These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8474980)

  • 41. The mouse carcinogenicity study is no longer a scientifically justifiable core data requirement for the safety assessment of pesticides.
    Billington R; Lewis RW; Mehta JM; Dewhurst I
    Crit Rev Toxicol; 2010 Jan; 40(1):35-49. PubMed ID: 20144135
    [TBL] [Abstract][Full Text] [Related]  

  • 42. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
    Rose K
    Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
    [TBL] [Abstract][Full Text] [Related]  

  • 43. International group agrees to write world cancer standard.
    IMS Ind Med Surg; 1973 Oct; 42(9):26-7. PubMed ID: 4147852
    [No Abstract]   [Full Text] [Related]  

  • 44. Advancing the 3Rs in regulatory toxicology - Carcinogenicity testing: Scope for harmonisation and advancing the 3Rs in regulated sectors of the European Union.
    Annys E; Billington R; Clayton R; Bremm KD; Graziano M; McKelvie J; Ragan I; Schwarz M; van der Laan JW; Wood C; Öberg M; Wester P; Woodward KN
    Regul Toxicol Pharmacol; 2014 Jul; 69(2):234-42. PubMed ID: 24768934
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice.
    Battershill JM; Fielder RJ
    Hum Exp Toxicol; 1998 Apr; 17(4):193-205. PubMed ID: 9617631
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Status of occupational cancer in Lithuania.
    Everatt R; Jankauskas R; Kuciauskaité A
    Int J Occup Environ Health; 2006; 12(1):24-7. PubMed ID: 16523979
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evolution of European Union legislation of herbal medicinal products and its transposition to national legislation in 1965-2007: case Finland.
    Koski SM; Laitinen-Parkkonen P; Airaksinen M
    Int J Health Plann Manage; 2015; 30(3):260-75. PubMed ID: 24375722
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High-priority carcinogenic occupational agents and activities for health surveillance in Brazil.
    Guimarães RM; Rohlfs DB; Baêta KF; Dos Santos RD
    Rev Bras Med Trab; 2019; 17(2):254-259. PubMed ID: 32270128
    [TBL] [Abstract][Full Text] [Related]  

  • 49. From hazard identification to weighing the benefits and drawbacks of prevention.
    Vainio H; Weiderpass E
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):28-33. PubMed ID: 16005922
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Medical device regulation in the United States and the European Union: a comparative study.
    Chai JY
    Food Drug Law J; 2000; 55(1):57-80. PubMed ID: 12296349
    [No Abstract]   [Full Text] [Related]  

  • 51. Carcinogenic hazard.
    Br Med J; 1967 Jul; 3(5559):189-90. PubMed ID: 6067549
    [No Abstract]   [Full Text] [Related]  

  • 52. Occupational cancer in Spain.
    González CA; Agudo A
    Environ Health Perspect; 1999 May; 107 Suppl 2(Suppl 2):273-7. PubMed ID: 10350510
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Are occupational exposure limits becoming more alike within the European Union?
    Schenk L; Hansson SO; Rudén C; Gilek M
    J Appl Toxicol; 2008 Oct; 28(7):858-66. PubMed ID: 18381691
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [European Economic Community directive on protection of workers from risks of exposure to noise: problems of interpretation and application].
    Rossi L
    Med Lav; 1987; 78(1):15-27. PubMed ID: 3614083
    [No Abstract]   [Full Text] [Related]  

  • 55. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [A new update of the SIMLII Guidelines on carcinogens].
    Pira E; Giachino GM; Discalzi G
    G Ital Med Lav Ergon; 2011; 33(3):300-7. PubMed ID: 22073679
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Environmental carcinogenic agents and cancer prevention: risk assessment and management].
    Tsugane S
    Gan To Kagaku Ryoho; 2013 Nov; 40(11):1436-40. PubMed ID: 24231696
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Animal carcinogenicity studies: implications for the REACH system.
    Knight A; Bailey J; Balcombe J
    Altern Lab Anim; 2006 Mar; 34 Suppl 1():139-47. PubMed ID: 16555967
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dietary Supplements: Foods, Medicines, or Both? A Controversial Designation with Unspecific Legislation.
    Pereira C; Barros L; Ferreira ICFR
    Curr Pharm Des; 2017; 23(19):2722-2730. PubMed ID: 28124610
    [TBL] [Abstract][Full Text] [Related]  

  • 60. European regulation model for herbal medicine: The assessment of the EU monograph and the safety and efficacy evaluation in marketing authorization or registration in Member States.
    Qu L; Zou W; Wang Y; Wang M
    Phytomedicine; 2018 Mar; 42():219-225. PubMed ID: 29655689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.